Cohen Milstein Sellers & Toll LLP is investigating claims on behalf of investors in Profound Medical Corp. (“Profound”) (NASDAQ: PROF). To learn about your legal options, please complete the form on this page or contact Partner Molly Bowen at mbowen@cohenmilstein.com.
CASE BACKGROUND
Profound is a commercial-stage medical device company that develops and markets therapies for the ablation of diseased tissue. On March 6, 2025, Profound announced that the Audit Committee in discussion with Profound’s auditors identified an error which overstated revenue by $472,000 in the first quarter of 2024. Profound determined that the financial statements issued for the first three quarters of 2024 should no longer be relied upon and would be restated and reissued. On this news, Profound’s stock price fell 5.9%, to close at $6.86 per share on March 7, 2025.
NEXT STEPS
If you suffered a significant loss on your investment in PROF and are interested in learning more, you are invited to click here to hear from a member of the Cohen Milstein team or contact Partner Molly Bowen at mbowen@cohenmilstein.com.
OUR FIRM
With more than 100 attorneys in eight offices, Cohen Milstein is one of the largest plaintiff-side law firms in the U.S., with more than four decades of experience litigating securities fraud cases. We have recovered billions of dollars for investors, including $1 billion last year as co-lead counsel in In re Wells Fargo & Company Securities Litigation, and are perennially recognized as one of the best securities practice groups in the country by legal publications such as The National Law Journal, Law360, Chambers USA, and The Legal 500. For more information, visit www.cohenmilstein.com.
Prior results do not guarantee a similar outcome. This may be considered Attorney Advertising.
CONTACT INFORMATION
Molly Bowen, Esq.
Cohen Milstein Sellers & Toll PLLC
Washington, D.C. Office
Email: mbowen@cohenmilstein.com
Website: www.cohenmilstein.com